OVERVIEW OF EARLY STUDIES
Vascular endothelial growth factor (VEGF) 2 had been characterized as a heparin binding angiogenic growth factor displaying high specificity for endothelial cells (1, 2) . Vascular permeability factor (VPF) had been characterized as a protein that promotes extravasation of proteins from tumor-associated blood vessels (3) . It was subsequently realized that the permeability-inducing factor and the endothelial cell growth factor are encoded by a single VEGF gene, and that several VEGF isoforms are produced from this gene by alternative splicing to form active disulfide-linked homodimers (4) (5) (6) .
These initial discoveries were followed by the identification of specific VEGF receptors, first at the level of binding/cross-linking studies (7, 8) and then by identification of the VEGFR-1 (flt-1) and VEGFR-2 (KDR/ flk-1) genes that encode VEGF specific tyrosine-kinase receptors. These receptors are characterized by the presence of seven immunoglobulin-like domains in their extracellular parts and can therefore be regarded as a new subfamily of tyrosine-kinase receptors (9, 10) ( Fig. 1) . Important advances were also made regarding the biological role of VEGF. It was discovered that VEGF is expressed in spatial and temporal association with physiological events of angiogenesis in vivo (11, 12) . Inhibition of VEGF activity by neutralizing antibodies or by the introduction of dominant negative VEGF receptors into endothelial cells of tumor-associated blood vessels resulted in the inhibition of tumor growth and in tumor regression, indicating that VEGF is a major initiator of tumor angiogenesis (13, 14) . Furthermore, it was found that VEGF expression is potentiated by hypoxia and that the potentiation of VEGF production in hypoxic areas of solid tumors contributes significantly to VEGF-driven tumor angiogenesis (15, 16) . VEGF-induced angiogenesis was also found to play an important role in the etiology of several additional diseases associated with abnormal angiogenesis (17, 18) and in wound repair (19) .
These advances were accompanied by the identification of additional growth factors belonging to the VEGF family that share common receptors with VEGF. The discovery of placenta growth factor (PlGF) (20) was followed by the recent discovery of three additional growth factors belonging to the VEGF family (VEGF B-D) and by the discovery of an additional receptor (VEGFR-3) belonging to the VEGF receptor family. A summary of the interactions of the VEGF family growth factors with the various VEGF receptors is presented in Fig. 1 . However, because of space limitations, this review does not cover the biology of these VEGF-related factors except when such studies relate directly to VEGF. The reader will find additional information regarding these growth factors in recent reviews (21, 22) . Studies that have concentrated on the role of VEGF in embryonic development are covered partially for similar reasons. These studies are also covered in greater depth in recent reviews (23) (24) (25) .
THE ROLE OF VEGF AND ITS RECEPTORS IN VASCULOGENESIS AND ANGIOGENESIS
Initial findings indicating that VEGF is a prime regulator of angiogenesis and vasculogenesis have sparked research that has concentrated primarily on the mechanisms by which VEGF regulates vasculogenesis and angiogenesis during development and on the role of VEGF in the etiology of diseases that are characterized by deregulated angiogenesis.
The role of VEGF in the early development of the vasculature
The importance of VEGF as a central regulator of vasculogenesis was demonstrated in studies that have used the technique of targeted gene disruption in mice. Even animals that lack one of the two VEGF alleles die before birth because of defects in the development of the cardiovascular system (26, 27) . These observations indicate that the development of the cardiovascular system depends on the generation of precise VEGF concentration gradients and that a decrease in the amounts of the VEGF produced during the development of the embryo may lead to decreased angiogenesis with fatal consequences. Likewise, disruption of the genes encoding the VEGF tyrosine-kinase receptors VEGFR-2 (28) and VEGFR-1 (29) formation in homozygous animals. Embryos lacking the VEGFR-2 gene die before birth because differentiation of endothelial cells does not take place and blood vessels do not form (28) . A recent study has indicated that VEGFR-2 is required for the differentiation of endothelial cells and for the movement of primitive precursors of endothelial cells from the posterior primitive streak to the yolk sac, a precondition for the subsequent formation of blood vessels (30) . Disruption of the gene encoding the VEGFR-1 receptor did not prevent the differentiation of endothelial cells in homozygous animals, but the development of functional blood vessels from these endothelial cells was severely impaired (29) . Activation of the VEGFR-1 receptor promotes cell migration but does not seem to induce cell proliferation efficiently (31, 32) . It is thus possible that decreased cell migration or defects in endothelial cell-cell or cell-matrix interactions result in the defective organization of blood vessels in mice lacking functional VEGFR-1 (29) .
Hypoxia-driven retinal angiogenesis as a model for the role of angiogenesis during organ development
Hypoxia-induced VEGF production may provide the driving force that stimulates the angiogenesis that accompanies organ formation during development. Perhaps the best-studied example of such an event is the development of the retina and the associated network of retinal blood vessels. The picture that has emerged from the retina studies may also be true for the development of vascular systems in other organs. As the retina develops, astrocytes and neuronal precursors spread out and migrate away from the existing blood vessels. As the distance between the astrocytes and the existing vasculature increases, the astrocytes encounter progressively increasing hypoxic conditions. The astrocytes are more sensitive to hypoxia than the comigrating neuronal cells, and thus serve as hypoxia sensors. The hypoxia stimulates the astrocytes to produce VEGF, and the VEGF sets in motion an angiogenic response (33, 34) . A VEGF concentration gradient is formed that stimulates the growth of new blood vessels toward the VEGF-producing astrocytes. The result is that growing blood vessels follow the astrocytes that continue to migrate outward. As the hypoxic pressures ease after the arrival of the blood vessels, the production of VEGF by the astrocytes decreases. However, a certain threshold concentration of VEGF is required to inhibit apoptosis of the endothelial cells and is essential for the stabilization of the newly formed blood vessels. The falling levels of VEGF cause disassembly of some of these vessels, leaving intact a vascular network that is finely tuned to respond to the demands of the organ (35) . The remaining vessels are later stabilized and rendered insensitive to VEGF withdrawal by pericytes that follow in the wake of the endothelial cells to cover the newly formed blood vessels (36) .
Deregulated VEGF production results in angiogenic diseases of the retina
When cells lose the ability to control the synthesis of VEGF for any number of reasons, angiogenic disease ensues. In retinopathy of prematurity babies are placed in hyperoxygenated incubators because their lungs are not yet fully developed. This causes the astrocytes that are the sensors of hypoxia during the development of the retina to decrease VEGF production, causing newly formed blood vessels to regress and halting the orderly process of retinal angiogenesis during retina development. When the babies are moved out of the incubators, all the cells in the retina suddenly experience extreme hypoxia and produce simultaneously large amounts of VEGF. This overproduction results in rampant angiogenesis, which is not as finely choreographed as the angiogenesis that takes place during normal retinal development. The ensuing deregulated growth of blood vessels is the cause of blindness in babies that have been subjected to such treatment (37, 38) . A similar sequence of events can also be seen in other types of retinopathies in which partial or general ischemia of the retina is accompanied by overexpression of VEGF and hyperproliferation of blood vessels leading to blindness (17, 18, 39, 40) . This model is also supported by recent experiments that have demonstrated hyperproliferation of blood vessels in transgenic mice engineered to overproduce VEGF in retinal cells (41) .
When tissues are exposed to high concentrations of VEGF, additional abnormalities besides the hyperproliferation of blood vessels can be observed. Newly formed blood vessels of quail embryos exposed to high concentrations of VEGF undergo unregulated and excessive fusion of vessels that results in the formation of vessels with abnormally large lumens. This unregulated fusion leads in extreme cases to the formation of fused vascular sacs that obliterate the identity of individual vessels (42) . If, in contrast, the VEGF supply is reduced or completely inhibited, the result is impaired angiogenesis, which can lead to the inhibition of organ development. A truncated soluble VEGFR-1 was used to inhibit angiogenesis during the development of the corpus luteum in a rat model of hormonally induced ovulation. The inhibition of angiogenesis resulted in the complete inhibition of corpus luteum development (43) . These experiments support the hypothesis that the availability of angiogenic factors such as VEGF may be a major limiting factor that controls the extent of organ development and growth (44) .
The role of VEGF in tumor angiogenesis
Even though tumors are composed of dedifferentiated cells and do not exhibit an organized structure, from the point of view of angiogenesis a growing tumor may be viewed as a developing new organ. Angiogenesis is as essential for the growing tumor as it is for a developing organ such as the corpus luteum, since the delivery of blood-borne nutrients to the tumor cells is essential for their survival (43, 45) . Therefore the production of angiogenic factors by tumorigenic cells is essential for the development of solid tumors (46) . Initial studies have revealed that when VEGF signaling is inhibited, tumor angiogenesis and, consequently, tumor growth are impaired (13, 14) . VEGF also contributes to the development of tumors because of its ability to induce permeabilization of blood vessels. VEGF induces the formation of fenestrations in blood vessels (47, 48) and the formation of vesiculo-vacuolar organelles that form channels through which blood-borne proteins can extravasate (49) . This leads to the formation of an extravascular fibrin gel, which provides a matrix that supports the growth of endothelial cells and tumor cells and allows invasion of stromal cells into the developing tumor (50) .
In many types of tumors, elevated levels of VEGF production can often be detected in tumor cells located at the extreme periphery of the tumor where there is no hypoxia. It was subsequently observed that activated oncogenes that are part of the ras/MAP-kinase signal transduction pathway potentiate VEGF mRNA expression (51, 52) . Hypoxia-independent production of VEGF by tumorigenic cells can also be brought about by the inactivation of tumor suppressors such as p53 (53, 54) or by exogenous factors such as hormones or growth factors (55) . The molecular mechanisms by which these inducers affect VEGF production in normal and tumor cells are discussed in greater detail in the section dealing with the regulation of VEGF production.
As tumors expand, the cells within the expanding mass of the tumor are frequently deprived of oxygen because their distance from the nearest blood vessels increases. This results in the generation of hypoxic regions within tumors; the tumorigenic cells within these hypoxic areas respond by the stimulation of VEGF production, which then triggers angiogenesis using mechanisms similar to the mechanisms by which astrocytes sense hypoxia and induce angiogenesis in the developing retina. This results in particularly high levels of VEGF expression in hypoxic regions, which are usually located near necrotic areas within tumors (56) . The generality of this mechanism of VEGF induction explains why VEGF seems to be involved in the induction of tumor angiogenesis in so many types of diverse tumors. Another VEGF-related mechanism by which tumor angiogenesis can be induced involves production of VEGF-like proteins by viruses. The AIDS virus protein, HIV-1/Tat, can bind and activate VEGFR-2 (57). This probably represents a mechanism by which the AIDS virus enhances the angiogenic stimuli provided by Kaposi sarcoma herpes virus-encoded proteins (58), contributing to the development of Kaposi sarcoma in AIDS patients.
The use of VEGF and VEGF function inhibitors as drugs for various diseases associated with angiogenic disorders
The initial studies indicating that inhibition of VEGF signal transduction can inhibit tumor progression (13, 14) were followed by studies that have indicated that inhibition of VEGF signaling inhibits the development of many types of tumors (59) . Recent studies also suggest that inhibition of VEGF function abrogates tumor metastasis, possibly because the tumor cells come into contact with a lesser concentration of blood vessels (60) . These observations have sparked intense efforts directed at the development of efficient inhibitors of VEGF production and VEGF signal transduction for anti-tumorigenic purposes. Efforts to inhibit VEGF-induced tumor angiogenesis include the development of humanized neutralizing anti-VEGF monoclonal antibodies (61), inhibitory soluble VEGF receptors (43, 62, 63) , antisense VEGF mRNA expressing constructs (64, 65) , VEGF-toxin conjugates (66), antagonistic VEGF mutants (67) , and inhibitors of VEGF receptor function (60, 68, 69) . All these strategies hold promise, and it remains to be seen whether one of these approaches will lead to the development of an efficient inhibitor of VEGF-induced tumor angiogenesis.
The angiogenic properties of VEGF have also been exploited recently to induce in vivo angiogenesis for the treatment of two types of diseases associated with impaired blood supply. In some cases, VEGF was delivered to the sites of interest as a protein (70) . In other cases expression plasmids containing the VEGF cDNA or recombinant viruses were used in a gene therapy approach (71) (72) (73) . Successful attempts aimed at induction of collateral blood vessels in ischemic heart disease, critical limb ischemia, and reendothelialization by VEGF have been reported recently (70, (74) (75) (76) , and efforts are continuing.
THE REGULATION OF VEGF PRODUCTION
The regulation of VEGF production by growth factors, cytokines, and other extracellular molecules VEGF is a key regulator of angiogenesis, and its expression in producing cells is regulated by a plethora of external factors. Cytokines, growth factors, and gonadotropins that do not stimulate angiogenesis directly can modulate angiogenesis by modulating VEGF expression in specific cell types, and thus exert an indirect angiogenic or anti-angiogenic effect. tors that can potentiate VEGF production include fibroblast growth factor 4 (FGF-4) (77), PDGF (78) , tumor necrosis factor a (79), transforming growth factor b (TGF-b) (80), keratinocyte growth factor (KGF) (81), IGF-I (82), interleukin 1b (IL-1b) (83) , and IL-6 (84) . Other cytokines such as IL-10 and IL-13 can inhibit the release of VEGF (85) . An interesting example illustrating the complexity of the regulation of VEGF production during a biological process is the regulation of VEGF production during dermal wound healing. The expression of KGF is strongly potentiated during wound repair (86) . KGF, in turn, induces VEGF production in keratinocytes. In addition, hydrogen peroxide, a VEGF-inactivating oxidant (87) produced by neutrophils that invade the wound as part of the healing process, also potentiates VEGF production by keratinocytes (88) . The production of VEGF in keratinocytes is also strongly induced by UV-B radiation, again as part of a wound repair mechanism that involves angiogenesis (88) . Another small molecule that up-regulates VEGF expression is nitric oxide. Nitric oxide contributes to the blood vessel-permeabilizing effects of VEGF and to VEGF-stimulated vasodilatation (89) (90) (91) . The production of nitric oxide is in turn up-regulated by VEGF, indicating that a positive feedback loop exists between these two factors (92, 93) .
The mechanism by which hypoxia regulates VEGF production
Hypoxia and hypoglycemia are major stimulators of VEGF expression (15) . The production of other VEGF family members such as VEGF-B, VEGF-C, and PlGF does not seem to be potentiated by hypoxia even though some of these factors such as VEGF-C are strong angiogenic factors in their own right (94, 95) . The mechanisms that regulate VEGF production by oxygen availability have therefore received particular attention in recent years and are slowly being worked out. The mechanisms responsible for induction of VEGF and erythropoietin expression are similar (96) . Hypoxia-induced transcription of VEGF mRNA is apparently mediated, at least in part, by the binding of hypoxia-inducible factor 1 (HIF-1) to an HIF-1 binding site located in the VEGF promoter (97, 98) . It turns out that some mechanisms that lead to elevated VEGF production independently of hypoxia actually short-circuit the normal hypoxia sensing mechanism that regulates VEGF expression. For example, it was observed that the oncogene v-src can induce expression of HIF-1, thereby short-circuiting the HIF-1-dependent hypoxia sensing mechanism and leading to increased expression of VEGF (99) . Several additional HIF-1-like factors regulate VEGF production, but these transcription factors are not as well characterized (100, 101) . In addition to the induction of transcription, hypoxia promotes the sta- (105) . It is clear that additional proteins stabilize the VEGF mRNA, but their identity is still unknown.
Recent evidence indicates that the hypoxia-mediated elevation in VEGF transcription is also mediated by sites that are found in the 5 untranslated region of the VEGF mRNA (UTR), which is particularly long. The 5 UTR contains an alternative transcription initiation site and an active internal ribosomal entry site (IRES) located downstream of this alternative initiation site. MRNA initiated from this alternative start site contains the IRES. The translation of such uncapped mRNA is probably regulated primarily by the IRES and may be advantageous under conditions in which cap-dependent translation is inhibited, as is the case under stressful conditions such as the conditions prevailing during hypoxia (106, 107) .
Regulation of VEGF expression by the von HippelLandau (vHL) and p53 genes
Inactivation of tumor suppressors is an additional mechanism that leads to overexpression of VEGF in tumor cells. Cerebellar hemangioblastomas and human renal carcinomas are highly vascular, nonnecrotic, and presumably nonhypoxic tumors producing high levels of VEGF. Cells derived from such tumors contain mutations in the gene encoding the vHL tumor suppressor gene (108) . This observation suggest that mutations in the vHL gene are associated with increased angiogenesis, and it was indeed found that cells from such tumors display increased VEGF expression as a result of the inactivation of vHL (109, 110) . Wild-type vHL inhibits the production of several hypoxia-regulated proteins such as the GLUT-1 glucose transporter gene in addition to VEGF. vHL inhibition of VEGF expression is mediated by transcriptional and posttranscriptional mechanisms (111, 112) . At the posttranscriptional level, vHL inhibits the activity of protein kinase C zeta and delta (113) . In the absence of wild-type vHL, these kinases are active and the VEGF mRNA is stabilized as a result of the constitutive interaction of several proteins that are normally induced by hypoxia with a 500 base region in the 3 UTR (54). At the transcriptional level, vHL forms a complex with the Sp1 transcription factor and inhibits SP1-mediated VEGF expression as a result of the binding of SP1 to a specific region in the VEGF promoter (111) . These Sp1 binding sites are also important for PDGF-induced VEGF expression; mutations that inhibit Sp1 binding also abolish PDGF-induced VEGF expression (78) . The expression of PDGF-BB is also potentiated by hypoxia (114) . Another tumor suppressor associated with the control of VEGF expression seems to be P53. The loss of the wild-type P53 is associated with increased angiogenesis in developing tumors (115) . Wild-type P53 was identified as an inhibitor of VEGF production (116) , and mutated P53 was observed to potentiate VEGF expression (53) . However, a recent report apparently contradicts these findings and indicates that wild-type P53 may not function as an inhibitor of VEGF expression (117) .
THE VEGF SPLICE VARIANTS AND THE ROLE OF CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCANS

Similarities and differences between the VEGF splice forms
Five human VEGF mRNA species encoding VEGF isoforms of 121, 145, 165, 189, and 206 amino acids (VEGF ) are produced by alternative splicing of the VEGF mRNA (5, 6, 118, 119 ). An important biological property that distinguishes the different VEGF isoforms is their heparin and heparan-sulfate binding ability. VEGF 121 lacks the amino acids encoded by exons 6 and 7 of the VEGF gene (120) and does not bind to heparin or extracellular matrix (121) . The addition of the 44 amino acid-long peptide encoded by exon 7 of the VEGF gene distinguishes VEGF 165 from VEGF 121 and confers on VEGF 165 a heparin binding ability (121, 122) . VEGF 145 is distinguished by the presence of the 21 amino acid peptide encoded by exon 6. These amino acids contain a second independent heparin binding domain and also contain elements that enable the binding of VEGF 145 to the extracellular matrix (119) . VEGF 189 and VEGF 206 contain the peptides encoded by exons 6 and 7 and display a higher affinity to heparin and heparan-sulfates than VEGF 145 or VEGF 165 . VEGF 189 is not secreted into the medium of VEGF 189 -producing cells. It is sequestered on heparan-sulfate proteoglycans of cell surfaces and in the extracellular matrix, and there are indications that it is less active than either VEGF 121 or VEGF 165 in vivo (123) . Proteases such as plasmin can cleave it and release an active soluble proteolytic fragment of 110 amino acids (VEGF 110 ) (124, 125) . The three secreted VEGF splice forms VEGF 121 , VEGF 145 , and VEGF 165 induce proliferation of endothelial cells and in vivo angiogenesis (119, 121, 126) . When expression of the splice variants was examined, it was found that most cell types produce several VEGF variants simultaneously. Usually the 121 and 165 forms were the predominant forms, but expression of the 189 form could also be seen in most VEGF-producing cell types (127) . In contrast, VEGF 145 expression seems to be more restricted, and it was found to be expressed in cells derived from reproductive organs (119, 128, 129) .
The interaction between VEGF and cell-surface heparan-sulfates and its role
The heparin binding forms of VEGF can bind to cellsurface and extracellular matrix-associated heparansulfate proteoglycans and can release angiogenic factors such as bFGF, which are stored on heparansulfates of the extracellular matrix (130) . This observation is significant because VEGF and bFGF synergize with respect to their ability to induce angiogenesis (131) . Extracellular matrix-associated heparans-sulfate proteoglycans may also function as an extracellular storage place for the heparin binding VEGF isoforms (121) . Heparan-sulfate proteoglycans regulate the interaction of several heparin binding growth factors with their respective receptors and, consequently, their biological activity (132) . Early experiments have indicated that the binding of icantly the binding of native VEGF 165 to VEGFR-2. Oxidized VEGF 165 and VEGF 121 lose their ability to bind to VEGFR-2. Cell-surface heparan-sulfate proteoglycans such as glypican (134) fulfill a chaperonelike role and can restore the VEGFR-2 binding ability of oxidized VEGF 165 (S. Gengrinovitch, unpublished results). In contrast, the VEGFR-2 binding ability of VEGF 121 cannot be restored by heparan-sulfate proteoglycans after oxidative damage (87) . This observation may explain why VEGF 121 was reported to be much less potent than VEGF 165 by some researchers (135) , whereas others report smaller differences in activity (87, 136) . It is possible that VEGFs sustain various degrees of damage during their purification from cells or bacteria expressing recombinant VEGF and that such damage can be readily detected in the case of VEGF 121 , because cell-surface heparan-sulfates do not restore the activity of such damaged VEGF 121 .
Several studies indicate that heparan-sulfates may bind to VEGF receptors such as VEGFR-2 and regulate their VEGF 165 binding ability (137, 138) . However, the binding of VEGF 121 to VEGFR-2 is not affected by heparin or heparan-sulfate proteoglycans, indicating that heparan-sulfates probably cannot modulate the VEGF 121 binding ability of this particular receptor (87) . However, the VEGF 121 binding ability of other types of VEGF receptors may be directly affected by heparan-sulfates (122) .
THE VEGF RECEPTORS
Tyrosine-kinase receptors of VEGF Two VEGF receptors belonging to the tyrosine-kinase receptor family have been identified and cloned: the VEGFR-1 and the VEGFR-2 receptors (9, 10, 139, 140) . Along with the VEGFR-3 receptor, which is expressed in lymph vessels (141) and binds VEGF-C and VEGF-D, these receptors form a subfamily distinguished by the presence of seven immunoglobulinlike loops in their extracellular part and a split tyrosine-kinase domain in their intracellular part (142) (Fig. 1) . The VEGFR-2 and VEGFR-1 receptors are expressed predominantly in endothelial cells, but a few additional types of cells express one or both of these receptors. The VEGFR-1 receptor is expressed in trophoblast cells (143) , monocytes (31) , and renal mesangial cells (144) . VEGFR-2, on the other hand, is also expressed in hematopoietic stem cells, megakaryocytes, and retinal progenitor cells (145, 146) . In the retinal, two functional VEGFR-2 forms are expressed as a result of alternative splicing (147) . In addition, there are tumorigenic cell types that express VEGFR-2 or VEGFR-1. These include, for example, malignant melanoma cells (122, 148, 149) . The VEGFR-2 and VEGFR-1 receptors are probably activated by all VEGF isoforms but fulfill somewhat Fig. 1 , but only the VEGF isoforms can bind to VEGFR-1 and to VEGFR-2. Both receptors are glycosylated; in the case of VEGFR-2, only the final glycosylated form is capable of undergoing autophosphorylation in response to VEGF (150) .
The expression of VEGFR-2 and VEGFR-1 was reported to be affected by hypoxia, although to a lesser extent than that of VEGF. The transcription of VEGFR-1, but not that of VEGFR-2, is enhanced by hypoxia (151) . VEGFR-2 production is also up-regulated under hypoxic conditions, but the mechanism responsible for the induction seems to be posttranscriptional (152) . This hypoxia-induced change in VEGFR-2 and VEGFR-1 expression may be triggered indirectly, since VEGF potentiates the expression of both receptor types (153, 154) .
The interaction of VEGF with VEGFR-1 and VEGFR-2
Two separate domains of VEGF interact with VEGFR-2 and VEGFR-1. Alanine-scanning mutagenesis has revealed that Arg(82), Lys (84) , and His(86), are critical for the binding of VEGF to VEGFR-2, while Asp(63), Glu(64), and Glu (67) are required for the binding of VEGF to VEGFR-1. These binding domains are located at opposite ends of the VEGF monomer. In the mature VEGF dimer, the monomers are linked in a rough 'head-to-tail' fashion (with a large overlap) by disulfide bridges so that the main VEGFR-2 binding domains are at opposite ends of the molecule, as are the main VEGFR-1 binding domains ( Fig. 2A, B) (155, 156) . This spatial arrangement is in agreement with observations indicating that mutations within the VEGFR-2 binding site of VEGF have a minimal effect on the binding of VEGF to VEGFR-1, and that mutants affecting the VEGFR-1 binding site of VEGF do not affect the binding of VEGF to VEGFR-2 (155) . Furthermore, mutated VEGF deficient in VEGFR-2 binding ability did not induce proliferation of endothelial cells, whereas mutants deficient in their VEGFR-1 binding ability were still able to induce endothelial cell proliferation (155) . Nevertheless there is considerable overlap in the binding domains that interact with VEGFR-1 and VEGFR-2 at the groove formed between the VEGF monomers with which both VEGF receptors interact ( Fig. 2A, B) (157) . The arrangement of the receptor binding sites on VEGF indicates that a VEGF dimer may be able to bind and link together two VEGF receptors to form signaling homo-or heterodimers of receptors (Fig. 2C) (157, 158) . Indeed, there is some evidence indicating that VEGFR-2 and VEGFR-1 can form heterodimers after VEGF binding (159) . In the case of VEGFR-1, it was recently determined that the VEGF binding site is located in the second and third immunoglobulin-like loops and that two VEGFR-1 receptors can be linked by a VEGF bridge (157) . It was also determined that the fourth immunoglobulin-like loop contains a receptor dimerization domain (157, (160) (161) (162) (Fig. 1) . The second and the third immunoglobulin-like loops of VEGFR-2 are also sufficient for VEGF binding (158) ; its fourth immunoglobulinlike loop may also function as a dimerization domain, although there is no experimental data as yet to prove that assumption. The c-kit receptor that belongs to the PDGF subfamily of tyrosine-kinase receptors contains five immunoglobulin-like domains (as compared to seven in VEGF receptors). This receptor also possesses a dimerization domain located in its fourth immunoglobulin-like loop and a ligand binding site in the second and third immunoglobulin-like loops (163) . These structural similarities indicate that the VEGF and PDGF tyrosine-kinase receptor subfamilies are evolutionarily linked; this assumption was strengthened by a study that compared the structure of VEGFR-1 with the structure of several receptors belonging to the PDGF receptor family (164) .
Biological responses mediated by the activation of VEGFR-1 and VEGFR-2
Activation of the VEGFR-2 receptor by VEGF in cells devoid of VEGFR-1 results in a mitogenic response, while the activation of VEGFR-1 by VEGF in cells lacking VEGFR-2 does not induce cell proliferation (32, 165) . However, activation of VEGFR-1 by VEGF does induce cell migration, a response that is also induced as a result of VEGFR-2 activation by VEGF (31, 166, 167) . These results indicate that the signal transduction cascades induced by VEGFR-1 and VEGFR-2 are somewhat different. The information regarding the signaling cascades induced by each of these receptors is limited, and it is not yet completely clear why VEGFR-1 does not induce cell proliferation in response to VEGF and VEGFR-2 does. VEGF promoted the binding and phosphorylation of the Shc and Nyc adapters, Grb-2 binding, and MAP kinase activation in porcine aortic endothelial cells expressing recombinant VEGFR-2. In contrast, MAP kinase was not activated by VEGF in cells expressing recombinant VEGFR-1 in two separate studies (32, 168) . It is therefore possible that VEGFR-1 does not induce cell proliferation, because it does not activate MAP kinase. The SHP-1 and SHP-2 SH2 protein-tyrosine phosphatases physically associate with VEGFR-2 after stimulation with VEGF, raising the interesting possibility that both molecules participate in the modulation of VEGF-induced signals (168) . Eventually, activation of the VEGF receptors results in the generation of proteases that are required for the breakdown of the basement membrane of blood vessels in the first steps of angiogenesis (169) (170) (171) , in the expression of specific integrins required for angiogenesis (172) , and, finally, in the initiation of cell proliferation and cell migration.
The VEGF 165 -specific receptor neuropilin-1
Endothelial cells also contain VEGF receptors possessing a lower mass than either VEGFR-2 or VEGFR-1 (133) . It was subsequently found that these smaller VEGF receptors of the endothelial cells are isoform specific and bind to VEGF 165 , but not to VEGF 121 . It was therefore recognized that these receptors are not related to the VEGFR-1 or VEGFR-2 receptors that bind to both VEGF isoforms (87) . It was previously observed that several types of nonendothelial cells express these VEGF 165 -specific receptors (133) , and an additional search revealed several types of prostate and breast cancer cell lines that express unusually large amounts of these isoform-specific receptors (173) . The binding of VEGF 165 to these receptors is apparently mediated by amino acids residing at the carboxyl-terminal part of the exon 7-encoded peptide of VEGF 165 (173, 174) . The genes encoding these receptors were identified by using a combination of VEGF 165 affinity chromatography and expression cloning. The affinity purification approach revealed that the receptors seen in breast cancer MDA-MB-231 cells are encoded by neuropilin-1 (167), a receptor previously identified as a receptor for several types of semaphorins. Semaphorins were initially characterized as factors that act as repellents of nerve growth cones (175, 176) . In addition, the expression cloning approach has led to the identification of another VEGF 165 receptor, which turned out to be the product of the closely related gene, neuropilin-2 (167, 175) . It was recently observed that neuropilin-1 also functions as a receptor for the heparin binding form of PlGF, PlGF-2, but not for PlGF-1 (177) . The neuropilins have a short intracellular domain ( Fig. 1) and are therefore unlikely to function as independent receptors. Indeed, no responses to VEGF 165 were observed when cells expressing neuropilin-1 but no other VEGF receptors were stimulated with VEGF 165 (167) . Nevertheless, gene disruption studies indicate that neuropilin-1 is probably an important regulator of blood vessel development as mouse embryos lacking a functional neuropilin-1 gene die because their cardiovascular system fails to develop properly (178) . It is therefore likely that neuropilin-1 is a VEGF 165 coreceptor. This assumption is supported by experiments showing that VEGFR-2 binds VEGF 165 more efficiently in cells expressing neuropilin-1, and that this potentiating effect is subsequently translated into a better migratory response to VEGF 165 gration of endothelial cells equally well. This observation may indicate that neuropilin-1 is not able to function as a VEGFR-1 coreceptor, since PlGF was reported to induce cell migration via activation of the VEGFR-1 receptor (177, 179) .
The identification of neuropilin-1 as a coreceptor of VEGFR-2 may explain why the cardiovascular system of neuropilin-1 0/0 embryos fails to develop normally (178) . The identification of neuropilin-1 as a coreceptor of VEGFR-2 may provide an alternative explanation as to why VEGF 121 , a VEGF splice variant that does not bind to neuropilin-1, seems to be a less active mitogen than VEGF 165 . However, it should be pointed out that the measured differences between the mitogenic activities of VEGF 121 and VEGF 165 are divergent in different studies because of unknown reasons (119, 136) . The identification of neuropilins as VEGF 165 receptors also suggests that the different semaphorins may play a role in angiogenesis by interacting with neuropilins expressed in endothelial cells and, conversely, that VEGF 165 may activate neuropilin receptors of neuronal cells. Additional isoform-specific VEGF receptors may also exist, as suggested by a study in which a different VEGF 165 -specific receptor was described (180) . However, the gene encoding this receptor has not yet been identified.
CONCLUSIONS AND FUTURE DIRECTIONS
The last 3 years have witnessed an ever-growing interest in VEGF that has resulted in the publication of more than 1100 research papers. It was therefore impossible to cite all the relevant publications. In many instances there were several publications from different laboratories reporting similar findings. In such cases, due to space constraints, only one publication was cited.
The research conducted after the discovery of VEGF revealed that VEGF is a central regulator of angiogenesis and vasculogenesis. Several diseases, such as cancer, are characterized by abnormal angiogenesis, and it was realized that in many cases these diseases are accompanied by the aberrant production of VEGF. Moreover, it was realized that modulation of VEGF function may contribute to a successful therapeutic treatment of these diseases. However, at the moment VEGF signal transduction is not sufficiently understood. It is therefore likely that the study of VEGF signal transduction will be an area of intensive investigation in the near future. Research aimed at the elucidation of the mechanisms that fine-tune VEGF production is also likely to be at the center of attention. The understanding of these processes is essential for the successful development of methods aimed at the modulation of VEGF-induced angiogenesis.
VEGF and the VEGF family members represent but one set of proteins of a whole set of regulatory factors acting in concert to shape networks of mature, functional blood vessels (181) . There are indications that different angiogenic factors such as bFGF and VEGF may promote angiogenesis by using subtly different mechanisms (172) . It is thus reasonable to assume that a major research effort will be concentrated in the future on the mechanisms by which the activity of different angiogenic and anti-angiogenic factors is coordinated. These future research efforts should lead to a better understanding of angiogenesis and, consequently, to the development of better drugs aimed at the treatment of diseases associated with angiogenic disorders.
